|Bid||39.70 x 1000|
|Ask||39.51 x 1000|
|Day's Range||38.97 - 40.09|
|52 Week Range||33.42 - 46.29|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||279.86|
|Earnings Date||Feb 01, 2022 - Feb 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.87|
It hasn't been the best quarter for Boston Scientific Corporation ( NYSE:BSX ) shareholders, since the share price has...
Investors are optimistic about Boston Scientific (BSX) owing to its solid third-quarter performance and impressive value-added acquisitions.
Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System consists of two cardiac rhythm management (CRM) devices intended to work together to coordinate therapy: the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Modular Pacing System (MPS), which is designed to be the first leadless pacemaker capable of delivering both brady